Lara Meisner

US·SEC (Form 4)

Bicara Therapeutics Inc.Viridian Therapeutics, Inc.\DE

Cumul. flow

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (19 ops.)

€4.1M

Latest filing published 01 Oct 2025 for Bicara Therapeutics Inc., €266k.

Filing timeline

BuySale

Lara Meisner

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

T+90 mean return

-28.7%

Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.

Signal history

Lara Meisner: trading record in brief

Lara Meisner discloses dealings in 2 companies, chiefly Viridian Therapeutics, Inc.\DE and Bicara Therapeutics Inc. We count 37 filings; the first trade dates from 15 November 2022 and the latest from 29 September 2025.

No open-market purchase appears, only 19 sales worth €4.1M. Other entries cover 18 option exercises. Since January 2025: no purchases and 5 sales on the market.

The newest entry dates from 1 October 2025: an open-market sale of €425k, in Bicara Therapeutics Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.

Companies and markets linked to Lara Meisner

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Bicara Therapeutics Inc. (US)Viridian Therapeutics, Inc.\DE (US)

Declarations12 total

◇
Lara Meisner
Chief Legal OfficerExecutives29 Sept 2025Bicara Therapeutics Inc.
312,495 USD0SEC
33,807 shares@ US$9.2435Common StockSEC:0001883986-25-000009:0
◇
Lara Meisner
Chief Legal OfficerExecutives15 Sept 2025Bicara Therapeutics Inc.
86,268 USD12SEC
15,829 shares@ US$5.4513.4% of flowCommon StockSEC:0001883986-25-000006:0
◇
Lara Meisner
Chief Legal OfficerExecutives16 Jun 2025Bicara Therapeutics Inc.
86,268 USD13SEC
15,829 shares@ US$5.4515.8% of flowCommon StockSEC:0002023658-25-000085:0
◇
Lara Meisner
Chief Legal OfficerExecutives14 Mar 2025Bicara Therapeutics Inc.
431,346 USD19SEC
79,146 shares@ US$5.45100.0% of flowCommon StockSEC:0000950170-25-041546:0
◇
Lara Meisner
Chief Legal OfficerExecutives15 Jun 2023Viridian Therapeutics, Inc.\DE
52,255 USD11SEC
2,269 shares@ US$23.034.2% of flowCommon StockSEC:0000899243-23-015998:0
◇
Lara Meisner
Chief Legal OfficerExecutives2 Jun 2023Viridian Therapeutics, Inc.\DE
26,250 USD11SEC
1,875 shares@ US$14.002.1% of flowCommon StockSEC:0000899243-23-014615:0
▼
Lara Meisner
General Counsel and SecretaryExecutives9 Mar 2023Viridian Therapeutics, Inc.\DE
871,257 USD18SEC
29,971 shares@ US$29.0772.1% of flowCommon StockSEC:0000899243-23-007996:0
◇
Lara Meisner
General Counsel and SecretaryExecutives23 Jan 2023Viridian Therapeutics, Inc.\DE
114,482 USD12SEC
4,971 shares@ US$23.039.2% of flowCommon StockSEC:0000899243-23-002674:0
◇
Lara Meisner
General Counsel and SecretaryExecutives20 Dec 2022Viridian Therapeutics, Inc.\DE
13,818 USD11SEC
600 shares@ US$23.031.1% of flowCommon StockSEC:0000899243-22-039217:0
◇
Lara Meisner
General Counsel and SecretaryExecutives15 Dec 2022Viridian Therapeutics, Inc.\DE
6,909 USD11SEC
300 shares@ US$23.030.6% of flowCommon StockSEC:0000899243-22-039056:0
◇
Lara Meisner
General Counsel and SecretaryExecutives12 Dec 2022Viridian Therapeutics, Inc.\DE
13,818 USD11SEC
600 shares@ US$23.031.1% of flowCommon StockSEC:0000899243-22-038520:0
◇
Lara Meisner
General Counsel and SecretaryExecutives15 Nov 2022Viridian Therapeutics, Inc.\DE
113,750 USD12SEC
8,125 shares@ US$14.009.6% of flowCommon StockSEC:0000899243-22-036044:0

12 of 12 declarations

Lara Meisner

Insider track record

Lara Meisner: trading record in brief

Companies and markets linked to Lara Meisner

Similar companies

Related executives